en Other Other پژوهشي orginal article <span style="font-size:12pt"><span style="line-height:16.0pt"><span style="font-family:&quot;Times New Roman&quot;,serif"><b><i><span style="font-size:9.0pt">Background & Aims</span></i></b><b><span style="font-size:9.0pt">: </span></b><span style="font-size:9.0pt">Fever and neutropenia are major causes of mortality in cancer patients. This study compares the effectiveness of cefepime monotherapy with a ceftriaxone&ndash;amikacin combination in treating these complications. </span></span></span></span><br> <span style="font-size:12pt"><span style="line-height:16.0pt"><span style="font-family:&quot;Times New Roman&quot;,serif"><b><i><span style="font-size:9.0pt">Materials & Methods</span></i></b><b><span style="font-size:9.0pt">:</span></b><span style="font-size:9.0pt"> In a randomized clinical trial, 60 febrile neutropenic children with cancer at Shahid Motahari Hospital, Urmia, were assigned to receive either cefepime monotherapy or ceftriaxone&ndash;amikacin combination therapy. The hospital length of stay, time to defervescence, and frequency of therapy escalation were compared between the two groups.</span></span></span></span><br> <span style="font-size:12pt"><span style="line-height:16.0pt"><span style="font-family:&quot;Times New Roman&quot;,serif"><b><i><span style="font-size:9.0pt">Results</span></i></b><b><span style="font-size:9.0pt">:</span></b><span style="font-size:9.0pt"> The cefepime group had a shorter hospital stay, fewer febrile episodes, reduced antipyretic use, and less frequent antimicrobial escalation compared to the combination group. No significant differences were observed in laboratory results between admission and discharge in either group.</span></span></span></span><br> <span style="font-size:12pt"><span style="line-height:16.0pt"><span style="font-family:&quot;Times New Roman&quot;,serif"><b><i><span style="font-size:9.0pt">Conclusion</span></i></b><b><span style="font-size:9.0pt">: </span></b><span style="font-size:9.0pt">Cefepime monotherapy was significantly more effective than ceftriaxone&ndash;amikacin combination therapy in managing fever and neutropenia in pediatric cancer patients.</span> <b><span style="font-size:9.0pt"></span></b></span></span></span><br> <span style="font-size:12pt"><span style="background:#d9d9d9"><span style="line-height:16.0pt"><span style="font-family:&quot;Times New Roman&quot;,serif"><span style="font-size:9.0pt"></span></span></span></span></span> Amikacin, Cefepime, Ceftriaxone, Amikacin, Fever, Neutropenia, Pediatric 227 234 http://ijrabms.umsu.ac.ir/browse.php?a_code=A-10-350-1&slc_lang=en&sid=1 Zahra Ghelichkhan gkhan.z@umsu.ac.ir 10031947532846004186 10031947532846004186 Yes Department of Clinical Pharmacy, School of Pharmacy, Urmia University of Medical SciencesUrmia University of Medical Sciences Sarah Mohsenzadeh sarahmzd96@gmail.com 10031947532846004187 0009-0003-3269-5142 No Dept of clinical pharmacy, School of pharmacy, Urmia University of Medical Sciences/ Motahari Children's Hospital, Urmia University of Medical Sciences Mehran Noroozi mehranxnoroozi@gmail.com 10031947532846004188 10031947532846004188 No Motahari Children's Hospital, Urmia University of Medical Sciences Farid Ghazizadeh gazizadef@gmail.com 10031947532846004189 10031947532846004189 No Motahari Children's Hospital, Urmia University of Medical Sciences